A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
NCT ID: NCT07225296
Last Updated: 2025-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
72 participants
INTERVENTIONAL
2025-11-12
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
In Part 1, a single oral dose will be administered under fasting conditions. In Part 2, once-daily dosing will be administered for 14 consecutive days under fasting conditions. Sequential cohorts will receive increasing doses, with dose escalation decisions based on safety and tolerability reviews by the Safety Review Committee (SRC). Six (6) cohorts (S1 to S6) are planned for evaluation in Part 1 (SAD), and Three (3) cohorts (M1 to M3) are planned for evaluation in Part 2 (MAD).
TREATMENT
QUADRUPLE
The randomization code will be generated by a designated individual under the supervision of a statistician. All site and sponsor personnel involved in the study, except for the pharmacist (or designee) preparing study medication, will remain blinded.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GNS-3545
Part 1 (SAD): Six participants will be randomized to receive a single dose of GNS-3545 at the assigned dose level, while two participants will receive matching placebo.
Part 2 (MAD): Six participants will be randomized to receive multiple doses of GNS-3545 at the assigned dose level once daily for 14 consecutive days, while two participants will receive matching placebo.
GNS-3545
GNS-3545 will be administered as oral tablets at assigned dose levels to six of the eight participants within each cohort in Part 1 (SAD) and Part 2 (MAD).
In Part 1, participants will receive a single dose on one occasion (Day 1). In Part 2, participants will receive daily dosing for 14 consecutive days.
GNS-3545 Placebo
Part 1 (SAD): Six participants will be randomized to receive a single dose of GNS-3545 at the assigned dose level, while two participants will receive matching placebo.
Part 2 (MAD): Six participants will be randomized to receive multiple doses of GNS-3545 at the assigned dose level once daily for 14 consecutive days, while two participants will receive matching placebo.
GNS-3545 Placebo
The placebo will be administered as oral tablets identical in appearance to the GNS-3545 tablets to two of the eight participants within each cohort in Part 1 (SAD) and Part 2 (MAD).
In Part 1, participants will receive a single placebo dose on one occasion (Day 1).
In Part 2, participants will receive once-daily placebo doses for 14 consecutive days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GNS-3545
GNS-3545 will be administered as oral tablets at assigned dose levels to six of the eight participants within each cohort in Part 1 (SAD) and Part 2 (MAD).
In Part 1, participants will receive a single dose on one occasion (Day 1). In Part 2, participants will receive daily dosing for 14 consecutive days.
GNS-3545 Placebo
The placebo will be administered as oral tablets identical in appearance to the GNS-3545 tablets to two of the eight participants within each cohort in Part 1 (SAD) and Part 2 (MAD).
In Part 1, participants will receive a single placebo dose on one occasion (Day 1).
In Part 2, participants will receive once-daily placebo doses for 14 consecutive days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male subjects must follow protocol specified contraception guidance
* Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing
* BMI ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit and body weight of ≥ 50 kg
* Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, or vital signs, as deemed by the PI or designee
* No ECG findings of clinical significance as judged by the PI or qualified designee
* Understands the study procedures in the ICF and be willing and able to comply with the protocol
Exclusion Criteria
* History or presence of clinically significant medical or psychiatric conditions
* History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study
* Surgical procedure or Administration of a live vaccination within 30 days prior to the first dose of the study drug
* History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing
* History or presence of hepatic impairment
* History or presence of significant cardiovascular conditions or risk factors
* Subjects with a higher risk of adverse events in the setting of blood pressure decreases
* History or presence of hypersensitivity to compounds related to the study drug excipients
* Allergy to non-latex band aids, adhesive dressing, or medical tape
* Female subjects of childbearing potential or Female subject with a positive pregnancy test or who is lactating
* Positive urine drug or serum alcohol results
* Positive results at the screening visit for HIV, HBsAg, or HCV, or a clinically significant history of infection within 3 months prior to screening
* Inability or unwillingness to avoid use of medications, supplements, or substances that may affect CYP enzymes, drug transporters, blood pressure, or QT/QTc interval within the specified washout periods prior to dosing
* Has been on a diet incompatible with the on-study diet, or unable to swallow multiple tablets by mouth
* Has donated or lost more than 500 mL of blood within 56 days prior to the first dosing, or Plasma donation within 7 days prior to the first dosing
* Subjects with dietary restrictions that would prevent subjects from consuming a high-fat/high-calorie meal
* Participation in another clinical study within 30 days or 5 half-lives of the product prior to the first dosing
* Any reason determined by the PI or designee, in their opinion, that would prevent the subject's participation in the study
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genosco Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pharmaron CPC, Inc.
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GNS-3545-P101
Identifier Type: -
Identifier Source: org_study_id